CN105315374A - 二硫键稳定的多价抗体 - Google Patents

二硫键稳定的多价抗体 Download PDF

Info

Publication number
CN105315374A
CN105315374A CN201510638852.8A CN201510638852A CN105315374A CN 105315374 A CN105315374 A CN 105315374A CN 201510638852 A CN201510638852 A CN 201510638852A CN 105315374 A CN105315374 A CN 105315374A
Authority
CN
China
Prior art keywords
fab
antibody
sequence
fabb
single domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510638852.8A
Other languages
English (en)
Chinese (zh)
Inventor
R·亚当斯
L·汉库克
S·P·海伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/002310 external-priority patent/WO2010035012A1/en
Application filed by UCB SA filed Critical UCB SA
Publication of CN105315374A publication Critical patent/CN105315374A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201510638852.8A 2009-09-25 2010-09-24 二硫键稳定的多价抗体 Pending CN105315374A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2009/002310 WO2010035012A1 (en) 2008-09-26 2009-09-25 Biological products
GBPCT/GB2009/002310 2009-09-25
GB1005063.1 2010-03-25
GBGB1005063.1A GB201005063D0 (en) 2010-03-25 2010-03-25 Biological products
CN201080042387.7A CN102549018B (zh) 2009-09-25 2010-09-24 二硫键稳定的多价抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080042387.7A Division CN102549018B (zh) 2009-09-25 2010-09-24 二硫键稳定的多价抗体

Publications (1)

Publication Number Publication Date
CN105315374A true CN105315374A (zh) 2016-02-10

Family

ID=42228366

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080042387.7A Expired - Fee Related CN102549018B (zh) 2009-09-25 2010-09-24 二硫键稳定的多价抗体
CN201510638852.8A Pending CN105315374A (zh) 2009-09-25 2010-09-24 二硫键稳定的多价抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201080042387.7A Expired - Fee Related CN102549018B (zh) 2009-09-25 2010-09-24 二硫键稳定的多价抗体

Country Status (12)

Country Link
US (1) US20120316324A1 (enExample)
EP (1) EP2480577B1 (enExample)
JP (2) JP5931730B2 (enExample)
CN (2) CN102549018B (enExample)
BR (1) BR112012006492A2 (enExample)
CA (1) CA2773286C (enExample)
EA (1) EA201200526A1 (enExample)
ES (1) ES2736649T3 (enExample)
GB (1) GB201005063D0 (enExample)
IN (1) IN2012DN02535A (enExample)
TR (1) TR201910213T4 (enExample)
WO (1) WO2011036460A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
GB201005064D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EA027160B1 (ru) * 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013034160A1 (en) * 2011-09-06 2013-03-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Methods for analyzing biological macromolecular complexes and use thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
MX351502B (es) * 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
HUE037909T2 (hu) * 2013-02-05 2018-09-28 Sanofi Sa Immuno-képalkotó ágens antitest-farmakon-konjugátum terápiával történõ alkalmazásra
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
SI2953975T1 (en) * 2013-02-05 2018-02-28 Sanofi An immuno-contrast agent for use in antibody-drug conjugate therapy
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
MX2015010350A (es) * 2013-02-26 2015-10-29 Roche Glycart Ag Moleculas de union a antigeno biespecificas que activan la celula t.
MX2015010843A (es) * 2013-02-26 2016-04-04 Roche Glycart Ag Moleculas biespecificas de union al antigeno que activan celulas t.
DK3039038T3 (da) * 2013-08-30 2021-02-08 Aprilbio Co Ltd Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil
PL3065774T3 (pl) 2013-11-06 2021-12-13 Janssen Biotech, Inc Przeciwciała anty-ccl17
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US10669343B2 (en) 2015-08-05 2020-06-02 Janssen Biotech, Inc. Anti-CD154 antibodies and methods of using them
BR112018012344A2 (pt) 2015-12-17 2018-12-04 Janssen Biotech Inc anticorpos que se ligam especificamente a hla-dr e seus usos
BR112018013677A2 (pt) * 2016-01-11 2019-01-22 Inhibrx Inc proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
ES3015094T3 (en) * 2017-06-05 2025-04-29 Numab Therapeutics AG Anti-hsa antibodies
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
WO2019000105A1 (en) 2017-06-30 2019-01-03 Zymeworks Inc. STABILIZED CHIMERIC FABES
JP7369127B2 (ja) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
CN110551216B (zh) * 2018-05-31 2022-11-18 信达生物制药(苏州)有限公司 多价抗ox40抗体及其用途
CN115698088A (zh) * 2020-06-30 2023-02-03 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
CN116829585A (zh) 2020-08-05 2023-09-29 辛德凯因股份有限公司 Il27受体结合相关的组合物和方法
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
BR112023001723A2 (pt) 2020-08-05 2023-05-02 Synthekine Inc Moléculas de ligação à gp130 e métodos de uso
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
CN117242088A (zh) 2020-08-05 2023-12-15 辛德凯因股份有限公司 Il10受体结合分子和使用方法
WO2022032023A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il23r binding molecules and methods of use
MX2023001490A (es) 2020-08-05 2023-04-27 Synthekine Inc Moleculas de union a il27r\03b1 y metodos de uso.
WO2022032025A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr binding synthetic cytokines and methods of use
US12286482B2 (en) 2020-08-05 2025-04-29 Synthekine, Inc. IL10RB binding molecules and encoding nucleic acids
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules that multimerise cd45

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040562A1 (en) * 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
CN101448853A (zh) * 2006-03-17 2009-06-03 比奥根艾迪克Ma公司 稳定的多肽组合物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE19653722C2 (de) 1996-12-10 2000-06-29 Brose Fahrzeugteile Beidseitig wirkende Verstellvorrichtung
EP0968291B1 (en) 1997-02-21 2004-01-28 Genentech, Inc. Antibody fragment-polymer conjugates
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
EP1151002A4 (en) * 1999-01-29 2002-05-02 Imclone Systems Inc KDR-SPECIFIC ANTIBODIES AND USES THEREOF
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
JP4955185B2 (ja) 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
AU2005250216B2 (en) 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
EP2520588A1 (en) 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2007227292B2 (en) * 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
PT2334705T (pt) * 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448853A (zh) * 2006-03-17 2009-06-03 比奥根艾迪克Ma公司 稳定的多肽组合物
WO2009040562A1 (en) * 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHENGBIN WU等: "Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin", 《NATURE BIOTECHNOLOGY 》 *
N. MARTIN YOUNG等: "Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond", 《FEBS LETTERS》 *
SUN-HEE JUNG等: "Design of Interchain Disulfide Bonds in the Framework Region of the Fv Fragment of the Monoclonal Antibody B3", 《PROTEIN》 *
YORAM REITER等: "Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments", 《NATURE BIOTECHNOLOGY》 *
YORAM REITER等: "Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions", 《BIOCHEMISTRY》 *
ZHENPING ZHU等: "Remodeling domain interfaces to enhance heterodimer formation", 《PROTEIN SCIENCE》 *
付勇等: "二硫键稳定的人源化抗肝癌单链抗体与人嗜酸性细胞神经毒素重组免疫毒素融合基因的构建及表达", 《西北国防医学杂志》 *
赵君等: "二硫键稳定的抗肝癌单链抗体-PE38融合基因的构建、表达与功能检测", 《细胞与分子免疫学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
WO2018121473A1 (zh) * 2016-12-28 2018-07-05 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体

Also Published As

Publication number Publication date
JP5931730B2 (ja) 2016-06-08
EP2480577B1 (en) 2019-04-10
GB201005063D0 (en) 2010-05-12
CA2773286C (en) 2020-10-20
EA201200526A1 (ru) 2012-11-30
JP2013505923A (ja) 2013-02-21
CN102549018B (zh) 2015-11-25
EP2480577A1 (en) 2012-08-01
IN2012DN02535A (enExample) 2015-08-28
ES2736649T3 (es) 2020-01-03
CN102549018A (zh) 2012-07-04
US20120316324A1 (en) 2012-12-13
WO2011036460A1 (en) 2011-03-31
BR112012006492A2 (pt) 2016-11-22
JP2016106126A (ja) 2016-06-16
CA2773286A1 (en) 2011-03-31
TR201910213T4 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
CN102549018B (zh) 二硫键稳定的多价抗体
CN102164965B (zh) 生物产品
US11427650B2 (en) Dual specificity antibody fusions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160210

WD01 Invention patent application deemed withdrawn after publication